Production of the Russian Sputnik-V vaccine in Egypt will begin in six months, said the management of the pharmaceutical company Minapharm, which about a year ago signed an agreement with the Russian Direct Investment Fund (RDIF), reports the Russian agency TASS.
According to the company, the process of transferring the vaccine production technology is being completed, the first samples produced have been sent to Russia for testing, and the final phase related to the approval of the vaccine by the competent Egyptian drug regulatory authority is being completed. All procedures will take six months.
Talks between Minapharm and RDIF were completed in April 2021. Under the signed contract, more than 40 million doses of vaccine will be produced annually. The vaccine production technology is delivered to Egypt in order to meet its own domestic needs and exports to other countries in the Middle East and Africa.
In Egypt, all vaccines approved by the WHO are currently in use, including Sinovac-Vaxera, which is based on Chinese technology. However, the most popular vaccines are Sputnik-V, Pfizer and Johnson & Johnson.
Source: ΑΠΕ-ΜΠΕ
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
